The latest content updates from the drugdevelopment-technology.com web site http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ http://www.drugdevelopment-technology.com/content/images/logo_big.gif http://www.drugdevelopment-technology.com/news/newssanofi-regeneron-announce-positive-phase-2a-results-dupilumab-asthma-patients http://www.drugdevelopment-technology.com/news/newssanofi-regeneron-announce-positive-phase-2a-results-dupilumab-asthma-patients Dupilumab targets the alpha subunit of the interleukin 4 receptor (IL-4R alpha), which modulates signaling of both IL-4 and IL-13, drivers of Th2 (Type 2 helper T cell) immune response. Tue, 21 May 2013 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newsabbvie-commences-phase-3-diabetic-nephropathy-study-atrasentan http://www.drugdevelopment-technology.com/news/newsabbvie-commences-phase-3-diabetic-nephropathy-study-atrasentan Research-based biopharmaceutical company AbbVie has started Phase 3 in study of investigational compound atrasentan on renal outcomes in patients with diabetic nephropathy. Tue, 21 May 2013 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newsr-tech-begins-patient-enrolment-phase-iii-severe-dry-eye-study http://www.drugdevelopment-technology.com/news/newsr-tech-begins-patient-enrolment-phase-iii-severe-dry-eye-study R-Tech Ueno has started patient enrolment in Phase I/II study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101) in the US for treating severe dry eye. Mon, 20 May 2013 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newspfizer-ends-inotuzumab-ozogamicin-phase-3-non-hodgkin-lymphoma-study http://www.drugdevelopment-technology.com/news/newspfizer-ends-inotuzumab-ozogamicin-phase-3-non-hodgkin-lymphoma-study Pfizer has stopped the Phase 3 randomised, open-label study (B1931008) of inotuzumab ozogamicin in relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL). Mon, 20 May 2013 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newsnovo-nordisk-announces-positive-results-from-phase-3-haemophilia-b-trial http://www.drugdevelopment-technology.com/news/newsnovo-nordisk-announces-positive-results-from-phase-3-haemophilia-b-trial Novo Nordisk has announced positive results from phase 3 trial with long-acting factor IX, glycopegylated recombinant factor IX (N9-GP), for treatment of haemophilia B. Sun, 19 May 2013 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newsnw-bio-commences-phase-iii-trial-of-dcvax-l-for-brain-cancer http://www.drugdevelopment-technology.com/news/newsnw-bio-commences-phase-iii-trial-of-dcvax-l-for-brain-cancer Northwest Biotherapeutics (NW Bio) has announced the commencement of a Phase III trial with DCVax-L for brain cancer at King's College Hospital in the UK. Sun, 19 May 2013 23:00:00 GMT http://www.drugdevelopment-technology.com/contractors/sterilisation/priorclave-autoclave/pressproven-autoclave-design-a-long-runner.html http://www.drugdevelopment-technology.com/contractors/sterilisation/priorclave-autoclave/pressproven-autoclave-design-a-long-runner.html Top-loading laboratory autoclaves are the longest serving stalwarts of the Priorclave steam steriliser range, a 100l model being the first produced and to leave the company's factory in 1988 when it started trading, and through dedicated service and … Fri, 17 May 2013 11:26:00 GMT http://www.drugdevelopment-technology.com/contractors/synthesis/bachem/pressbachem-adds-11-new-research-products-to-online-catalogue.html http://www.drugdevelopment-technology.com/contractors/synthesis/bachem/pressbachem-adds-11-new-research-products-to-online-catalogue.html Bachem is continuously expanding and updating its extensive range of biologically active peptides, amino acid derivatives, biochemicals and immunology products. Fri, 17 May 2013 11:03:00 GMT http://www.drugdevelopment-technology.com/news/newsfda-approves-xofigo-prostate-cancer-drug http://www.drugdevelopment-technology.com/news/newsfda-approves-xofigo-prostate-cancer-drug The USFDA has approved Xofigo (radium Ra 223 dichloride) for the treatment of advanced prostate cancer three months ahead of schedule under the priority review programme. Thu, 16 May 2013 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newstrillium-completes-dosing-in-phase-i-cystitisbladder-pain-syndrome-study-of-tti-1612 http://www.drugdevelopment-technology.com/news/newstrillium-completes-dosing-in-phase-i-cystitisbladder-pain-syndrome-study-of-tti-1612 Trillium Therapeutics, a wholly-owned subsidiary of Stem Cell Therapeutics has completed dosing in patients with interstitial cystitis/bladder pain syndrome (IC/BPS) in the Phase I study of TTI-1612. Thu, 16 May 2013 23:00:00 GMT http://www.drugdevelopment-technology.com/contractors/events/temperature-maintenance-of-biopharmaceuticals-usa-2013/ http://www.drugdevelopment-technology.com/contractors/events/temperature-maintenance-of-biopharmaceuticals-usa-2013/ After last year's highly successful launch of the Temperature Maintenance of Biopharmaceuticals, the conference will return to Boston, MA, on 5 - 6 June. Focusing on the most relevant and up-to-date ... Thu, 16 May 2013 16:23:00 GMT http://www.drugdevelopment-technology.com/news/newssoligenix-commences-phase-i-paediatric-crohns-disease-study-of-sgx203 http://www.drugdevelopment-technology.com/news/newssoligenix-commences-phase-i-paediatric-crohns-disease-study-of-sgx203 Clinical-stage biopharmaceutical company Soligenix has initiated a Phase I study of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) to treat paediatric Crohn's disease. Wed, 15 May 2013 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newssanofi-regeneron-announce-patient-enrolment-in-sarilumab-phase-iii-trials http://www.drugdevelopment-technology.com/news/newssanofi-regeneron-announce-patient-enrolment-in-sarilumab-phase-iii-trials Sanofi and Regeneron Pharmaceuticals have announced patient enrolment in two Phase III trials, Compare and Ascertain, to assess sarilumab as a treatment for rheumatoid arthritis (RA). Wed, 15 May 2013 23:00:00 GMT http://www.drugdevelopment-technology.com/contractors/contract_research/biovian/pressmeet-biovian-biotrinity-2013-european-biopartnering-and-investment-conference-14-16-may-2013-newbury-uk.html http://www.drugdevelopment-technology.com/contractors/contract_research/biovian/pressmeet-biovian-biotrinity-2013-european-biopartnering-and-investment-conference-14-16-may-2013-newbury-uk.html Meet Biovian at BioTrinity 2013 - European Biopartnering and Investment Conference - 14-16 May 2013, Newbury, UK. Wed, 15 May 2013 10:12:00 GMT http://www.drugdevelopment-technology.com/news/newsoncomed-initiates-phase-ib-ii-small-cell-lung-cancer-trial-of-omp-59r5 http://www.drugdevelopment-technology.com/news/newsoncomed-initiates-phase-ib-ii-small-cell-lung-cancer-trial-of-omp-59r5 OncoMed Pharmaceuticals has initiated a Phase Ib/II trial of anti-cancer stem cell therapeutic OMP-59R5 (Anti-Notch2/3) in small cell lung cancer (SCLC). Tue, 14 May 2013 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newsmirna-initiates-phase-i-trial-of-anti-cancer-drug-mrx34 http://www.drugdevelopment-technology.com/news/newsmirna-initiates-phase-i-trial-of-anti-cancer-drug-mrx34 MicroRNA therapy developer Mirna Therapeutics has commenced a Phase I trial of anti-cancer drug MRX34. Tue, 14 May 2013 23:00:00 GMT http://www.drugdevelopment-technology.com/projects/simbrinza-brinzolamidebrimonidine-tartrate-for-the-reduction-of-elevated-intraocular-pressure/ http://www.drugdevelopment-technology.com/projects/simbrinza-brinzolamidebrimonidine-tartrate-for-the-reduction-of-elevated-intraocular-pressure/ Simbrinza (brinzolamide/brimonidine tartrate) is a carbonic anhydrase inhibitor developed by Alcon, a division of Novartis. Mon, 13 May 2013 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newsmorphosys-commences-patient-dosing-in-phase-ii-study-of-lymphoma-drug http://www.drugdevelopment-technology.com/news/newsmorphosys-commences-patient-dosing-in-phase-ii-study-of-lymphoma-drug MorphoSys has commenced patient dosing in a Phase II study of anti-CD19 antibody MOR208 for the treatment of non-Hodgkin's lymphoma (NHL). Mon, 13 May 2013 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newsrelypsa-completes-enrolment-in-patiromer-phase-iii-programme-to-treat-hyperkalemia http://www.drugdevelopment-technology.com/news/newsrelypsa-completes-enrolment-in-patiromer-phase-iii-programme-to-treat-hyperkalemia Clinical-stage biopharmaceutical company Relypsa has finished enrolling patients with chronic kidney disease (CKD) in a pivotal Phase III programme of patiromer for the treatment of hyperkalemia. Mon, 13 May 2013 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newseli-lilly-reports-poor-results-from-phase-iii-diffuse-large-b-cell-lymphoma-study http://www.drugdevelopment-technology.com/news/newseli-lilly-reports-poor-results-from-phase-iii-diffuse-large-b-cell-lymphoma-study Eli Lilly and Company has announced that a Phase III study designed to evaluate enzastaurin as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL) has failed to yeild positive results. Sun, 12 May 2013 23:00:00 GMT